Syndesi Therapeutics

Chemin Du Cyclotron 6

1348 Ottignies-Louvain-La-Neuve

BE

Syndesi Therapeutics

Foundation date

19/12/2017

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment.

Upcoming events

Latest news

  • Indigo Diabetes announces first participant enrolled in the SHINE clinical trial

    18 hours ago

  • FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome

    Tuesday September 27th 2022

  • Pauwels Consulting takes over Science@Work

    Friday September 23rd 2022